Instrument Function Verification; Operating Instructions; Specimen Collection - Chrono-Log 490 4+4 Instruction Manual

b. Check the cable and make sure the Aggregometer has
power.
c. To retry, select "Aggregometer" from the ribbon, then
"Connect" from the dropdown menu.
d. Once AGGREGOMETER READY appears on the lower
right side of the status bar, close the AGGRO/LINK®
TM
Opti8 Software.
10. Start the vW CoFactor Opti8
During the software start-up, the computer will test the
communication. The Program will respond with
AGGREGOMETER READY on the lower right side of the status
bar when communication is established.
a. If communication is not established, then the Program
will continue searching and respond with A/L NOT
CONNECTED on the lower right side of the status bar if
connection cannot be established.
b. Check the cable and make sure the Aggregometer has
power.
c. To retry, select "Aggregometer" from the ribbon, then
"Connect" from the dropdown menu.
d. Once AGGREGOMETER READY appears on the lower
right side of the status bar, close the vW CoFactor
Opti8 TM Software.
11. The LCD display on each channel will show a temperature
reading. This reading will settle at the desired temperature
in approximately 15 minutes.
12. The System is now installed and ready for use.

INSTRUMENT FUNCTION VERIFICATION

1. Temperature Check – set to 37° in all channels.
2. Stirring - take a cuvette with stir bar and place in each
reaction well to observe it spinning.
3. Optical Circuit Function - insert a BLACK cuvette from P/N
322 Calibration Kit into the reaction well for PRP. Insert a
water cuvette from P/N 322 calibration kit into the reaction
well for PPP. Press and HOLD the SET BASELINE button and
observe the tracing at the 100% light transmission baseline.
Release the SET BASELINE button and observe a return to
the PRP 0% baseline.
4. Replace the BLACK cuvette with the other water cuvette
from P/N 322 calibration kit and observe the tracing near the
100% light transmission baseline.

OPERATING INSTRUCTIONS

For Model 490 4+/490 4+4, install the AGGRO/LINK® Opti8
Software as described previously under INSTALLATION section of
this manual.
For Model 490 4+DR/490 4+4DR the software for running the
AGGRO/LINK® Opti8 programs were installed at the factory.
TM
Before attempting to run aggregation testing, read the Software
section on page 10 and PROCEDURE – STEPWISE on page 11 of
this manual to learn the operation of AGGRO/LINK® Opti8
software.

SPECIMEN COLLECTION:

Preparation and Handling of Blood Specimens:
It is extremely important that care be taken in the collection,
handling, and preparation of the patient's blood specimen.
Document # 49044IM1
Revision 7.5
Dated February 16, 2017
TM
Software on the Computer.
TM
TM
Warning: Patient specimens should be handled as if they contain
infectious materials, in accordance with national guidelines for
Biosafety/Hazard Group 2. In the United States, the universal
precautions recommended by the Department of Labor,
Occupational Safety and Health Administration apply.
(Occupational Exposure to Blood Borne Pathogens; final rule (29
CFR 1910, 1030) FEDERAL REGISTER.
Essential precautions can be summarized as follows:
• Do not pipette by mouth.
Wear disposable gloves during all specimen and assay
•
manipulations.
• Avoid use of sharp-pointed or glass liquid handling devices,
which may puncture skin.
Do not smoke, eat, or drink in the laboratory area.
•
• Avoid splashing any liquid specimens and reagents and the
formation of aerosols.
Wash hands thoroughly on completion of a manipulation.
•
Patient Preparation:
Subjects for Optical platelet aggregation tests should be resting,
fasting and non-smoking. Subjects should avoid taking any
prescription or over-the-counter medications known to affect
platelet function for ten (10) days to two (2) weeks prior to the
test.
A partial list of medications with known antiplatelet effects
19
follow:
COX-1 Inhibitors (Acetylsalicylic acid)
•
Aspirin and all proprietary or over-the-counter (OTC)
preparations containing acetylsalicylic acid
• COX-1 and COX-2 Inhibitors (Nonsteroidal anti-
inflammatory drugs [NSAIDs])
Ibuprofen, Indomethacin, naproxen, Mefenamic acid
• COX-2 Inhibitors (Coxibs)
Celecoxib
Inhibitors of Platelet Receptors
•
Abciximab (α β ), Clopidogrel (P2Y
IIb 3
• RGD Peptomimetics
Eptifibatide, Tirofiban
Phosphodiesterase Inhibitors
•
Dipyridamole, Cilostazole
• Anticoagulants
Heparin, Warfarin, Direct Thrombin Inhibitors (lepirudin,
argatroban, bivalirudin)
• Cardiovascular Agents
β-adrenergic blockers (propranolol), Vasodilators
(nitroprusside, nitroclygerin), Diuretics (furosemide),
Calcium channel blockers
• Antimicrobials
β-lactams (penicillin, cephalosporins), Amphotericin
(antifungal), Hydroxychloroquines (antimalarial),
Nitrofurantoin
• Chemotherapeutics Agents
Asparaginase, Plicamycin, Vincristine
Psychotropics and Anesthetics
•
Thricyclic antidepressents (imipramine), Phenothiazines
(chlorpromazine), Local and general anesthesia (fluothane)
• Miscellaneous Agents
Clofibrate, Dextrans, Guaifenesin (expectorant),
Radiographic contrast
• Foods/Herbals
Alcohol, Caffeine (methylxanthine), Garlic, Onion, Ginger,
Fish Oil, Vitamins C and E.
7
), Prasugral (P2Y )
12 12